Glucagon-Like Peptide-1 Receptor Agonists for Chronic Weight Management.
Glucagon-Like Peptide-1 Receptor Agonists for Chronic Weight Management.
复制标题
作者：
肥胖率在过去几十年里一直在上升。随后，药物减肥药市场的受欢迎程度在过去几年里不断增长，以满足日益增长的需求。在最常用的体重控制处方药中，许多是胰高血糖素样肽-1受体激动剂(GLP-1激动剂)，也用于治疗2型糖尿病。有大量的研究比较不同临床试验的有效性并检查长期安全性，这些研究还在不断增加。这篇文献综述考察了在体重管理中非标签处方做法的兴起，重点是GLP-1激动剂。医生和患者应该意识到现有治疗方案的独特方面，非标签处方的影响，以及这些药物的效果。这篇综述强调了知情决策的重要性，以及进一步研究指导未来临床实践的必要性。
Rates of obesity have risen over the past few decades. Subsequently, the popularity of the pharmaceutical weight-loss drug market has grown over the past few years to meet growing demand. Among the most commonly prescribed drugs for weight management, many are glucagon-like peptide-1 receptor agonists (GLP-1 agonists) which are also utilized for the management of type 2 diabetes. There is a substantial and growing body of research comparing the efficacy of different clinical trials and examining long-term safety. This literature review examines the rise of off-label prescribing practices in the management of weight, with a focus on GLP-1 agonists. Physicians and patients should be aware of the unique aspects of existing treatment options, the impacts of off-label prescribing, and the effects of these medications. This review emphasizes the importance of informed decision-making, as well as the need for further research to guide future clinical practice.